IDP-wtLN10

General Information


DRACP ID  DRACP01769

Peptide Name   IDP-wtLN10

Sequence  AAKVVILKKATEYVES

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetics

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients Glioblastoma Blastoma EC50>100 μM CYTELL assay 72-96 h Patent
12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients Glioblastoma Blastoma EC50>100 μM CYTELL assay 72-96 h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01769

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C80H137N19O24

Absent amino acids  CDFGHMNPQRW

Common amino acids  AKV

Mass  201682

Pl  9.22

Basic residues  3

Acidic residues  2

Hydrophobic residues  8

Net charge  1

Boman Index  -899

Hydrophobicity  30

Aliphatic Index  121.88

Half Life 
  Mammalian: 1.4 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  1490

Absorbance 280nm  99.33

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US2020/0157150A1

Patent Title  Anticancer Peptides

Other Iinformation  Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017

Other Published ID  AU2018311129A1  CA3071601A1  CN111436200A  EP3661947A1  JP2020529429A  KR20200032730A  WO2019025432A1 




DRACP is developed by Dr.Zheng's team.